The text has been copied to the clipboard
Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.
Journal article

Addressing current challenges and future directions in immuno-oncology: expert perspectives from the 2017 NIBIT Foundation Think Tank, Siena, Italy.

  • Maio M Center for Immuno-Oncology, Medical Oncology and Immunotherapy, Istituto Toscano Tumori, University Hospital of Siena, V.le Bracci, 16, 53100, Siena, Italy. mmaiocro@gmail.com.
  • Coukos G Lausanne Branch, Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
  • Ferrone S Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
  • Fox BA Earle A. Chiles Research Institute at the Robert W. Franz Cancer Center, Providence Cancer Institute, Providence Portland Medical Center, 4805 NE Glisan, Portland, OR, 97213, USA.
  • Fridman WH Cancer, Immune Control and Escape Team, Cordeliers Research Center, INSERM UMRS 1138, Paris, France.
  • Garcia PL Merck, ZI de l'Ouriettaz, 1170, Aubonne, Switzerland.
  • Lahn M , Oberursel, Germany.
  • Provendier O Laboratoires Pierre Fabre, 45 Place Abel Gance, 92100, Boulogne-Billancourt, France.
  • Russo V Italian Network for Tumor Bio-Immunotherapy Foundation, Center for Immuno-Oncology, Istituto Toscano Tumori, University Hospital of Siena, 53100, Siena, Italy.
  • Rüttinger D Roche Pharma Research and Early Development, Roche Innovation Center Munich, Nonnenwald 2, 82377, Penzberg, Germany.
  • Shalabi A Cancer Research Institute, 29 Broadway, New York, NY, 10006-3111, USA.
  • Trajanoski Z Biocenter, Division of Bioinformatics, Medical University of Innsbruck, 6020, Innsbruck, Austria.
  • Viallet J , Malvern, PA, USA.
  • Wolchok JD Ludwig Center for Cancer Immunotherapy, Parker Institute for Cancer Immunotherapy, San Francisco, USA.
  • Ibrahim R Parker Institute for Cancer Immunotherapy, 1 Letterman Drive, San Francisco, CA, 94129, USA.
Show more…
  • 2018-12-20
Published in:
  • Cancer immunology, immunotherapy : CII. - 2019
English A collaborative think tank involving panellists from immuno-oncology networks, clinical/translational investigators and the pharmaceutical industry was held in Siena, Italy, in October 2017 to discuss the evolving immune-oncology landscape, identify selected key challenges, and provide a perspective on the next steps required in the translation of current research and knowledge to clinical reality. While there is a trend of combining new agents (e.g., co-stimulator agonists) with a PD-1/PD-L1 treatment backbone, use of alternative combination therapy approaches should also be considered. While the rapid evolution in systems biology provides a deeper understanding of tumor and tumor microenvironment heterogeneity, there remains the need to identify and define genuinely predictive biomarkers to guide treatment and patient selection. Cross-specialty and cross-sector collaboration, along with a broader collective data-sharing approach are key to optimizing immuno-oncology therapy in clinical practice. Continued support of younger research-clinicians is essential for future success in clinical, translational and basic science investigations.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/27812
Export to…

Statistics

Document views: 69 File downloads: